NovaBridge Biosciences (NBP)
NovaBridge Biosciences at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
NovaBridge Biosciences (NBP) is a Biotechnology company based in US with a market capitalization of $210.9M. Free cash flow was negative at -$20.6M. This page tracks NBP's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 32 employees · IPO Jan 17, 2020
Valuation
Valuation & price
$1.82as of May 17, 2026· -72.3% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
6.39
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$210.9M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$20.6M
Free cash flow (USD)
-$29.7M
Net debt
Net cash position
-48.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2017 → 2025
Free cash flow by year
2017 → 2025
Gross margin by year
2021 → 2023
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
2
Insider sells · 90 days
Earnings
Last report: 20-F/A filed Jun 16, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 6-K filingJul 24, 2026Filing
Annual General Meeting Notice
- 6-K filingJul 17, 2026Filing
Omnibus Share Incentive Plan
- Insider sellJul 7, 2026Filing
Insider Sell $4KXu Cong Claire · SVP, Clinical Development · $4K
- 6-K filingJun 29, 2026Filing
Management Change
- Insider sellJun 22, 2026Filing
Insider Sell $6KDennis Phillip Andrew · Chief Medical Officer · $5.6K
- 6-K filingJun 16, 2026Filing
FDA Fast Track Designation
- 6-K filingJun 16, 2026Filing
Change of Accountants
- Annual reportJun 16, 2026Filing
20-F Filed
- 6-K filingApr 22, 2026Filing
Management Change
- Annual reportApr 7, 2026Filing
Annual Report Filed
Questions
Frequently asked questions
What is NovaBridge Biosciences's market cap?
NovaBridge Biosciences (NBP) has a market capitalization of $210.9M.
What is NBP's P/E ratio?
A meaningful P/E ratio is not available for NBP — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is NBP's price-to-book (P/B) ratio?
NBP trades at 6.39 times book value per share.
Are insiders buying NBP stock?
SEC Form 4 filings show no open-market insider buys at NovaBridge Biosciences in the last 90 days (2 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.